Novel Coronavirus Information Center

Elsevier’s free health and medical research on novel coronavirus (2019-nCoV)

3D illustration of Coronavirus (© istock.com/Dr_Microbe)
3D illustration of Coronavirus (© istock.com/Dr_Microbe)

Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on Novel Coronavirus (also referred to as COVID-19 and its temporary title 2019-nCoV). All resources are free to access and include guidelines for clinicians and patients. Under the 'Research' tab you will find the latest early stage and peer-reviewed research from journals including The Lancet and Cell Press, as well as a link to the Coronavirus hub on ScienceDirect, where you will find every article relevant article to Coronavirus, SARS, and MERS freely available. Under the Clinical Solutions tab you will find resources for nurses, clinicians and patients, including FAQs on symptoms.


Introduction

Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier

Recent events have shown us (again) how rapidly a new disease can take root and spread. Such events are accompanied by an explosion of clinical and epidemiological information and research. The goal of this website is to open whatever resources we can to help public health authorities, researchers and clinicians contain and manage this disease. We will provide continually updated resources from Elsevier's content and experts. Our resources span scientific and medical journals and textbooks, educational products, and a variety of other resources, like travel precautions from the CDC and media posts of interest to our community. We have also created a  interactive global map of experts based on Scopus data.

Read more

Expert guidance and commentary

6 of the most common coronavirus questions the media is asking

By Rodney E. Rohde, PhD | Feb 6, 2020

Rodney E Rohde, PhDAs an infectious disease and clinical microbiology expert, Prof. Rodney E. Rohde of the Texas State University College of Health Professions receives daily calls from the media, government and university officials, and public health and professional organizations asking him about the emerging novel coronavirus outbreak. In this article, he shares some of the most common questions and his responses. Read more.

Prof. Rohde has also published two nCoV articles with the American Society for Microbiology (ASM):


Interactive map: global disease outbreak experts

The map represents the most active institutions researching disease outbreak and control. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications researching the coronavirus and related diseases such as SARS from 1996 to the present (Feb 6, 2020). We then used the resulting ~22,000 publications to identify the researchers and institutions that are working in these areas. The map shows the 500 most prolific global institutions, along with the 200 most prolific Chinese institutions by publication count.

Click on a pin to see more about the institution, the numbers of researchers and their publications. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.

Legend

Video: Novel Coronavirus Update

Livestreamed on Feb 6, 2020

JAMA Editor-in-Chief Howard Baucher, MD, interviews Anthony Fauci, MD, Director of the NIH National Institute of Allergy and Infectious Diseases.



Key facts for clinicians

By Margaret Trexler Hessen, MD | Updated Feb 3, 2020

Background: In December, China notified the World Health Organization of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, now called 2019-nCoV. Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Cases have now been reported in many part of mainland China and in other countries in Asia, Europe, the eastern Mediterranean, Australia, Asia Pacific and North America. Travel within China has been restricted  travel to and from China markedly reduced. Screening of travelers is being implemented in other countries and quarantine measures have been enacted under some circumstances. Despite these precautions, it is anticipated that more cases will be seen both inside China and internationally.

Novel coronaviruses have emerged as human pathogens in the past, notably associated with outbreaks of SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Current investigative methods and recommendations derive in some part from the experience of those epidemics.

Clinical presentation: The incubation period is thought to be 2 to 14 days. Symptoms include fever (which may be absent in persons at extremes of age or with immunocompromise), cough and dyspnea. Chest radiographs may show bilateral infiltrates. Clinical illness varies from mild to severe; about 25% of confirmed cases have been classified as severe, and there are increasing numbers of deaths. In early cases, mortality was associated with advanced age or comorbidities.

Diagnosis: Although respiratory infections (including influenza) are prevalent in the northern hemisphere during the winter, clinicians should inquire about travel history in persons presenting with respiratory illness. The possibility of 2019-nCoV infection should be suspected in persons who present with compatible clinical illness and exposure history. The US Centers for Disease Control (CDC) and World Health Organization (WHO) have slightly different criteria for whom to test, as noted below:

  • Recent travel (within 14 days) from Wuhan, Hubei Province, China (WHO). The CDC has broadened geographic criteria to include travel from Hubei Province — and for persons with fever and lower respiratory illness requiring hospitalization, travel from mainland China.
  • Close contact with a person suspected or known to have infection due to 2019-nCoV (WHO, CDC). The CDC defines close contact as being within 6 feet (2 meters) or within a room or care area for a prolonged period without personal protective equipment OR having direct contact with secretions of a person with 2019-nCoV infection.
  • Exposure to a healthcare facility in a country where hospital-associated nCoV infections have been reported (WHO).
  • The disease occurs in a healthcare worker who has been working in an environment where patients with severe acute respiratory infections are being cared for, without regard to place of residence or history of travel (WHO).
  • The person develops an unusual or unexpected clinical course, especially sudden deterioration despite appropriate treatment, without regard to place of residence or history of travel, even if another etiology has been identified that fully explains the clinical presentation (WHO).
  • In Hubei province only, a trained medical professional can now classify a suspected case of COVID19 as a clinically-confirmed case on the basis of chest imaging, rather than a laboratory confirmation (WHO, as of 13 Feb 2020)

In the United States, suspected cases should be reported immediately to local or state health departments, which will determine whether the patient meets clinical and epidemiologic criteria for disease and coordinate diagnostic testing of suspected patients through the CDC. Collection of specimens from the upper respiratory tract, lower respiratory tract and serum is recommended as a priority; other specimens, such as stool or urine, may be collected and stored to be tested at the discretion of the CDC. The CDC provides detailed information on collection and shipping of specimens for cases approved by local or state authorities. The CDC advises that testing for other respiratory pathogens by the provider should be done as part of the initial evaluation and should not delay specimen shipping to CDC.

If a patient with suspected 2019-nCoV infection tests positive for another respiratory pathogen, after clinical evaluation and consultation with public health authorities, they may no longer be considered a person under investigation.

Management: No specific antiviral agent is available for treatment of this infection, and there is no vaccine. Treatment is supportive and includes supplemental oxygen and conservative fluid management, as indicated by clinical condition. WHO provides detailed guidance on such supportive measures and cautions that severely ill patients should be treated empirically for other possible causes while diagnostic test results are pending.

Infection control measures are an integral part of management:

  • Provide the patient with a face mask and place the patient in a closed room (preferably with structural safeguards against airborne transmission).
  • Persons entering the room should follow standard, contact, and airborne precautions.
  • Patients managed at home are encouraged to self-isolate to a single area of the house (preferably with a separate bathroom) and to wear a face mask during any contact with household members.
  • The patient and all household members should follow diligent hand and cough hygiene.

Complications: Respiratory failure and septic shock occur in some patients. The case fatality rate is about 2 percent.

Margaret Trexler Hessen, MD, is an infectious disease specialist with 20 years of clinical practice experience and public health service, including outbreak management. She has been with Elsevier since 2010 and is currently Director, Point of Care.



Clinicians need reliable and current information to combat novel coronavirus

By Jonathan Temte, MD, PhD | January 27, 2020

Jonathan Temte, MD, PhD, Consultant, PracticeUpdate, ElsevierCoronaviruses are incredibly diverse, found in many animal species, and are commonly encountered in clinical practice during the cold and flu season, yet many primary care clinicians are not familiar with these respiratory pathogens. We rarely test for them, and when we do it’s usually when we’re looking for something else. Moreover, we have no specific treatments for these viruses.

The usual suspects have funny names: coronavirus HKU1, NL63, 229E and OC43. In our ongoing surveillance and epidemiological studies in school, clinics and longterm care settings, we find all four of these. There are two other coronaviruses that have been previously shown to infect humans: SARS (severe acute respiratory syndrome-associated coronavirus, or SARS-CoV), which emerged in 2003, and MERS (Middle East Respiratory Syndrome Coronavirus, or MERS-CoV), which emerged in 2012. SARS and MERS are associated with high case fatality rates.

Now a novel coronavirus, named 2019-nCoV, has emerged in China. There are hundreds of cases in China and multiple cases across the globe. The second case in the US was confirmed Friday in Illinois. We are extremely early in this rapidly expanding outbreak. With this evolving situation comes fear, misinformation and many unknowns. Accordingly, clinicians need to find reliable and current sources of credible information. A good place to start is the CDC resource page for healthcare professionals.

Jonathan Temte, MD, PhD, is Associate Dean for Public Health and Community Engagement and Professor of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health and former Chair of the Advisory Committee on Immunization Practices (ACIP). Jon currently serves as Chair of the Wisconsin Council on Immunization Practices and has been active on pandemic influenza and bioterrorism working groups for the state. He is a consultant for Elsevier's PracticeUpdate.


Elsevier Clinical Solutions

We've selected content from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education collections to share what we know to date about the novel coronavirus.

Clinical Overviews on ClinicalKey

Clinical Overviews are easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops Clinical Overviews through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.

Clinical Skills for Nursing

Clinical Skills for Nursing provides the highest quality evidence for nursing practice procedures for nurses to care for patients. Our Isolation Precautions and Personal Protective Equipment checklists align with CDC and OSHA guidelines:

Interprofessional Care Plans

These Interprofessional Care Plans provide an evidence-based and individualizable Interprofessional plan of care to manage fever and the possible development of pneumonia, which is consistent with the presentation of this virus. Using an interprofessional approach to patient care that aligns current evidence with the individual needs of the patient results in improved patient care outcomes.

Patient engagement resources

Patient engagement resources use plain language to support shared decision-making between patients and healthcare providers. The goal is to deliver the right message in the right way at the time the patient is most ready to learn. The following resources provide an overview of the novel coronavirus to help patients and their families understand their risk, identify signs and symptoms, and prevent it from spreading:


Video overview of Coronavirus from 3D4Medical - Watch now:


中文资源 (Chinese-language resources)

TitlePublished by (CN)Published by (EN)Link
Virology 
2019新型冠状病毒信息库   National Genomics Data Center

https://bigd.big.ac.cn/ncov

新型冠状病毒国家科技资源服务系统。共享:
1)第一株病毒毒种信息及其电镜照片
2)新型冠状病毒核酸检测引物和探针序列
国家微生物科学数据中心和国家病原微生物资源库 National Microbiological Data Center;
National Pathogen Resource Collection Center
http://nmdc.cn/#/nCoV
Diagnosis & Treatment Guidelines
新型冠状病毒感染的肺炎诊疗方案(试行第三版)(PDF可下载) 国家卫生健康委员会 National Health Commission http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml
湖北省新型冠状病毒感染的肺炎诊疗方案(试行第一版) 湖北省医疗救治专家组 Medical Expert Panel of Hubei Province https://xw.qq.com/cmsid/20200123A0KNOW00
《新型冠状病毒肺炎诊疗快速指南》 华中科技大学同济医学院附属同济医院专家组 Tongji Hospital, Tongji Medical College of HUST https://xw.qq.com/health/20200124010910/HLH2020012401091000
《武汉协和医院处置2019新型冠状病毒感染策略及说明》 华中科技大学同济医学院附属协和医院专家组 Xiehe Hospital, Tongji Medical College of HUST https://www.dxy.cn/bbs/newweb/pc/post/42662254
关于“新型冠状病毒感染的肺炎”诊疗建议方案(V2.0)中国医学科学院北京协和医院Peking Union Medical College Hospital, CAMShttps://new.qq.com/omn/HLH20200/HLH2020012501009300.html
医疗机构内新型冠状病毒感染预防与控制技术指南(第一版)国家卫生健康委员会National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml

新型冠状病毒实验室生物安全指南(第二版)国家卫生健康委员会National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml

新型冠状病毒感染的肺炎诊疗方案(试行第四版)国家卫生健康委员会National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67.shtml

新型冠状病毒感染的肺炎防控方案(第三版)国家卫生健康委员会National Health Commission

http://www.nhc.gov.cn/xcs/zhengcwj/202001/470b128513fe46f086d79667db9f76a5.shtml

新型冠状病毒感染的肺炎病例转运工作方案(试行)国家卫生健康委员会National Health Commissionhttp://www.nhc.gov.cn/xcs/zhengcwj/202001/ccee6ec0942a42a18df8e5ce6329b6f5.shtml
新型冠状病毒感染的肺炎患者遗体处置工作指引(试行)国家卫生健康委员会National Health Commissionhttp://www.nhc.gov.cn/yzygj/s7659/202002/163c26a24057489dbf64dba359c59a5f.shtml
Epidemic situation
 新型冠状病毒感染的肺炎疫情分布 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention

http://2019ncov.chinacdc.cn/2019-nCoV

    
Research articles and book chapters
Notes from the Field: An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province...[2020-01-22] 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/en/article/id/e3c63ca9-dedb-4fb6-9c1c-d057adb77b57 
A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019-2020[2020-01-21] 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c
中国新型冠状病毒感染病例首批临床数据报告(解读, The Lancet  Weichat Official Account The Lancet Weichat Official Account https://marlin-prod.literatumonline.com/pb-assets/Lancet/marketing/wechat/WeChat_website.jpg
引自《默里及纳达尔呼吸医学》,V Courtney Broaddus 主编,李为民、程德云主译,人民卫生出版社,2018 李为民、程德云主译,人民卫生出版社,2018 Elsevier, with content quoted from translation published by PMPH

Influenza

Pneumonia

Coronavirus

Patient Education
轻症疑似2019新型冠状病毒患者及密切接触人员如何进行自我管理 北京协和医院呼吸科 Respiratory Department, Peking Union Medical College Hospital, CAMS http://m.sohu.com/a/368777653_102327
《新型冠状病毒感染防护》   Elsevier Clinical Solutions 新型冠状病毒感染防护》
Institutional Special Reports
国家卫生健康委员会新型冠状病毒感染的肺炎专题 国家卫生健康委员会 National Health Commission http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml
中国疾病预防控制中心新型冠状病毒感染的肺炎专题 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/
中国疾病预防控制中心周报(English Version) 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/
丁香园丁香热点 丁香园 DingXiangYuan https://www.dxy.cn/bbs/newweb/pc/board/151/3484
疫情地图及趋势图丁香园DingXiangYuanhttps://3g.dxy.cn/newh5/view/pneumonia
Key Media Special Reports
抗击肺炎专题 今日头条 Beijing Byte Dance Technology Co., Ltd. https://www.toutiao.com/
#我在疫情第一线# 三联生活周刊 Sanlian Life Weekly https://s.weibo.com/weibo?q=%23%E6%88%91%E5%9C%A8%E7%96%AB%E6%83%85%E4%B8%80%E7%BA%BF%23&from=default

Video overview (Chinese language voice over)

全球冠状病毒研究机构及研究人员分布图

基于爱思唯尔独有的全球最大的引文摘要数据库Scopus,聚焦冠状病毒疫情爆发及疫情控制研究。通过关键词检索分析,得到了自1996年至今已发表的22000多篇文献。在科研表现世界地图中,展示了全球表现突出的500多所科研机构(发文量超过10篇含)。其中,中国的科研机构有200多所。在这200多所中国科研机构中,中国大陆有150所,中国香港有15所,中国台湾有43所。

中国的科研机构按照发文量来看,香港大学以2888篇占据首位,远远高于排在第二位的香港中文大学(1766篇),中国农科院以1519篇论文紧随其后。其他占据发文前十的科研机构还包括中国医学科学院、国立台湾大学、中科院微生物所、中国疾病预防控制中心、北京大学、华中农业大学和首都医科大学。除此之外,复旦大学、中国军事医学科学院、清华大学、华南农业大学、中山大学、中科院武汉病毒所也分别发表了超过400篇的相关科研论文。

通过互动地图,不仅可以概览全球特别是中国的相关研究机构分布,同时还可以通过放大或缩小地图来聚焦某个研究机构,靶定该机构的研究人员来进行深入分析,以获取更多有价值的信息。

注:按照发文量进行排名,地图中蓝色标记的为全球冠状病毒研究排名前500的机构,红色标记为中国排名前200的机构,紫色标记为排在全球前500机构中的中国机构。

Because Google is not available in China and various other countries, we are offering a local version of the map, enabling you also to download the data.

View the interactive version on Baidu


Research

In this section, you can find the following resources:

The Lancet Coronavirus hub

View this infographic and other coronavirus content on The Lancet's Coronavirus hub.

To assist health workers and researchers working under difficult and dangerous conditions to bring this outbreak to a close, The Lancet has created a Coronavirus hub page. This hub brings together new coronavirus content from The Lancet journals as it is published.

You can also find related information from Cell Press here

Content hubs from other publishers

Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | Chongqing VIP Information

Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.


Articles in Elsevier journals

Below are a selection of articles curated by our clinical solutions team and directly relevant to Novel Coronavirus (2019-nCov).

In addition to these, Elsevier has made more than 2,500 coronavirus-related articles freely available for the next six months (commencing 10/02/2019). You can find these articles here.

We will be updating this section continually.

More published research

Book chapters


Early-stage research (preprints on SSRN platform)

Emerging and rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.

SSRN, Elsevier’s world-leading platform devoted to the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.


Resources for drug discovery

Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we will use those tools to generate information relevant to combatting 2019-nCoV.


Download this and other infographics for the public from the WHO novel coronavirus website.  Download this and other infographics from the WHO's website Novel Coronavirus advice for the public.Here, you will find official guidance from major health organizations such as the CDC and WHO and media posts of interest to our community.

Official coronavirus guidance from various countries:

Argentina | Australia | Canada | Chile | China | Colombia | France | Germany | Mexico | Peru | Singapore | Spain | UK | US

In the media


Contributors


Written by

Elsevier Connect

Written by

Elsevier Connect

This site features daily stories for the global science, health and technology communities, written by experts in the field as well as Elsevier colleagues.